An interventional study of MRI (cardiac) off-label use gadolinium contrast (IND exempt) and MRI (cardiac) in Heart Failure With Preserved Ejection Fraction and Healthy, sponsored by University of California, Los Angeles. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-01.
Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Diagnostic
Heart failure is a clinical syndrome marked by breathlessness, even at low levels of exertion, general fatigue, and fluid retention and is estimated to affect 5.1 million people in the United States. Heart failure with preserved ejection fraction (HFpEF) means that the heart pumps enough blood to the body, but patients still have terrible symptoms. It is estimated to account for about 50% of all heart failure cases. Experts agree that impaired filling of the heart, perhaps due to "stiffness" of the heart muscle itself, critically underlies HFpEF. There is currently no clinical technique for measuring heart muscle (myocardial) stiffness; the very definition of "myocardial stiffness" remains poorly established. Consequently, the ability to study the mechanisms that underlie HFpEF is virtually non-existent, and limited treatment options will persist without significant advances. The objective of this project is to use an Equilibrium-Material-Stability (EMS) framework that couples patient-specific clinical MRI and heart pressure data in a computational model of the heart to diagnose changes in myocardial stiffness. The central hypothesis is that the new EMS framework for understanding the mechanisms of diastolic dysfunction in HFpEF will be more sensitive and outperform currently available approaches.
The study has three aims. The first aim of the project is to refine MRI techniques using "free-breathing" versus "breath-holding" measurements. Twenty-five normal volunteers will undergo MRI to refine "free-breathing" cardiac imaging and enable construction of patient-specific computer models of the heart. The second aim of the project is to validate and test the myocardial stiffness evaluation framework derived through the first objective in human subjects. Twenty-five normal volunteers will undergo MRI and the data from these images will be compared to specially constructed 3D printed models of the heart, enabling refinement of the EMS framework to separate structural stiffness from material stiffness. The third aim of the project is to measure changes in myocardial stiffness in patients with HFpEF. Thirty-three subjects with current diagnostic criteria for HFpEF will be evaluated at baseline and at six months to evaluate myocardial stiffness and cardiac MRI biomarkers. Specifically, this aim will establish the diagnostic sensitivity of the EMS framework with comparison to cardiac MRI biomarkers of increased stiffness, thereby providing mechanistic insight to one critical underlying cause of HFpEF.
University of California, Los Angeles is the lead sponsor of 1,167 studies on the registry; 192 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 69 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Healthy volunteers
1. Healthy adults
Patients with Heart Failure with Preserved Ejection Fraction
Exclusion Criteria:
Healthy volunteers
Patients with Heart Failure with Preserved Ejection Fraction
Exclusion Criteria:
Group 1 includes 25 healthy subjects recruited in Year 1 to undergo cardiac MRI without contrast.
Diagnostic Test: MRI (cardiac)
Group 2 includes 25 healthy subjects recruited in Year 2 to undergo cardiac MRI without contrast.
Diagnostic Test: MRI (cardiac)
Group 3 includes 33 patients with Heart Failure with Preserved Ejection Fraction (HFpEF) who will undergo cardiac MRI at baseline and at six months to assess diagnostic sensitivity of MRI measurement.
Diagnostic Test: MRI (cardiac) off-label use gadolinium contrast (IND exempt)
Clinical MRI
MRI without contrast
The sensitivity of the EMS framework with comparison to cardiac MRI biomarkers of increased stiffness, thereby providing mechanistic insight to one critical underlying cause of HFpEF.
Assess the diagnostic sensitivity of MRI method by analyzing baseline and six month longitudinal characteristics in myocardial stiffness measured in patients with HFpEF
Time frame: Five years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2018; primary completion for Sep 2021, 39 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles →